COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
21/01/2025
PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid [...]
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
21/01/2025
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by [...]
Olympia Pharmaceuticals Expands into Alabama with New Licensing, Bringing GLP-1s and More to Healthcare Providers
21/01/2025
Nation’s leading compound pharmacy is now available in 48 states ORLANDO, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility, is [...]
Welcoming Victor Bornsztejn as Senior Vice President of Commercial
21/01/2025
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is pleased to announce the appointment of Victor Bornsztejn as the [...]
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
21/01/2025
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
Completion of Offering and Increase in Registered Capital
21/01/2025
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO [...]
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
21/01/2025
- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( [...]
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
21/01/2025
Study showed online screening tool and patient education improved genetic testing completion rate SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and [...]
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
21/01/2025
Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant improvement over available treatments for serious conditions REDWOOD CITY, Calif., Jan. 21, 2025 [...]
Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network
21/01/2025
SAN FRANCISCO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adaptive Research Inc. announced that Prodigy Psychiatric Group has joined its clinical trial network, marking Adaptive Research's expansion into psychiatric research. [...]
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
21/01/2025
Thursday, January 23rd, 2025 at 4:15pm Eastern Time WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, [...]
Publication relating to transparency notifications
20/01/2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Publication relative à des notifications de transparence
20/01/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 20 janvier 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
20/01/2025
Saint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus [...]
Valneva annonce une réponse immunitaire robuste et durable chez les adolescents un an après une seule vaccination avec son vaccin contre le chikungunya
20/01/2025
Saint-Herblain (France), le 20 janvier 2025 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui de nouveaux résultats de Phase 3 positifs chez les adolescents [...]
ProDentim: The Breakthrough Oral Probiotic—Why ProDentim Is an Essential Dental Health Solution for 2025
20/01/2025
AKRON, Ohio, Jan. 20, 2025 (GLOBE NEWSWIRE) -- ProDentim enters the spotlight at a time when more individuals are rethinking conventional dental products, questioning the long-standing reliance on abrasive chemicals and [...]
Novo Nordisk A/S - share repurchase programme
20/01/2025
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]
Group FH ORTHO announced the Launch of JARVIS the New Round Baseplate for Reverse Prosthesis in the USA!
20/01/2025
HEIMSBRUNN, France, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Group FH ORTHO, a global leader in orthopedic prosthetic technologies, is proud to announce the launch of JARVIS, its new round baseplate for reverse shoulder [...]
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
20/01/2025
TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

Pages